The news of RBC Capital maintaining its 'Sector Perform' rating on Neurocrine Biosciences and raising the price target is likely to have a positive impact on the company's stock in the short term. Investors often use such ratings and price targets as a guide for making investment decisions. The increase in the price target suggests that the analyst sees potential for the stock's price to rise.